要約
A gene therapy can cost more than two million dollars. That number is genuinely shocking, and the explanation is not simply that companies are greedy. Development costs the same as any drug — often more — but the treatment is given once instead of daily for decades, and the number of eligible patients may be in the thousands rather than the millions. Divide a fixed cost by a very small number and you get a very large one.
Gene therapy pricing reflects development cost amortised over small eligible populations, bespoke manufacturing economics, and value-based arguments comparing one-time cost against decades of standard care. Payment models under discussion include outcomes-based agreements with clawbacks for treatment failure, instalment payments, and government-negotiated access programmes. The structural problem remains: durable one-time therapies fit poorly with insurance systems where members change insurer frequently, since the payer bearing the cost may not be the payer capturing the savings.
Where the money goes
The problem this creates
Roughly three-quarters of babies born with sickle cell disease each year are born in sub-Saharan Africa. A therapy priced in millions and requiring a transplant unit is unavailable to almost all of them. This is not a problem better science solves, and it is the reason serious effort is now going into in vivo approaches that would not need cell manufacturing or conditioning at all.
Sources
- U.S. Food and Drug Administration · 2023
FDA approves first gene therapies to treat patients with sickle cell disease ↗